Profil bibliographique

Matthew Kowgier

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

66Publications signalées

4054Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Hepatitis C virus researchOvarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyGenetic factors in colorectal cancer

Publications récentes

2026 articleOpenAlex

Torvutatug samrotecan (AZD5335) vs mirvetuximab soravtansine gynx in high FRα expressing tumors and torvutatug samrotecan vs chemotherapy in low FRα expressing tumors in patients with platinum resistant epithelial ovarian cancer in the randomized phase III TREVI OC 01/GOG 3127/ENGOT ov93 trial

Nicoletta Colombo, David O'Malley, Sandra Indiviglio, Matthew Kowgier et autres

0 citationsGynecologic Oncology

Accès ouvert 2026 articleOpenAlex

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial

Shannon N. Westin, Kathleen Moore, Hye Sook Chon, Jessica Thomes Pepin et autres

6 citationsGynecologic Oncology

2025 articleOpenAlex

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation

Kathleen N. Moore, Shannon N. Westin, Hye Sook Chon, Jessica Thomes Pepin et autres

4 citationsGynecologic Oncology

Accès ouvert 2025 articleOpenAlex

1117P Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial

Shannon N. Westin, Kraig Moore, Todd Tillmanns, C.L. Walters Haygood et autres

0 citationsAnnals of Oncology

2025 articleOpenAlex

Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, Jessica Thomes Pepin et autres

2 citationsInternational Journal of Gynecological Cancer

2024 articleOpenAlex

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial

Jean‐François Baurain, Hye Sook Chon, Jessica Thomes Pepin, Michael J. Sundborg et autres

8 citationsGynecologic Oncology

2024 articleOpenAlex

LB002/#1594 Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: exploratory analyses of biomarker/histological heterogeneity and efficacy in the DUO-E mismatch repair proficient subpopulation

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, Jessica Thomes Pepin et autres

5 citationsInternational Journal of Gynecological Cancer

2024 articleOpenAlex

LB001/#1593 Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib for endometrial cancer: mismatch repair deficient and/or microsatellite instability-high subpopulation efficacy analyses from the DUO-E trial

Els Van Nieuwenhuysen, Kathleen N. Moore, Todd Tillmanns, Christen L. Walters Haygood et autres

0 citationsInternational Journal of Gynecological Cancer

Accès ouvert 2024 articleOpenAlex

732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E

Stephanie V. Blank, Matthew McCollum, Charles Anderson, Kathryn P. Pennington et autres

2 citationsAnnals of Oncology

Accès ouvert 2024 conference-abstractOpenAlex

Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.

Jessica Thomes Pepin, Hye Sook Chon, Michael J. Sundborg, Michael A. Gold et autres

1 citationJournal of Clinical Oncology

2024 conference-abstractOpenAlex

Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.

Els Van Nieuwenhuysen, Jean‐François Baurain, Hye Sook Chon, Jessica Thomes Pepin et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2020 articleOpenAlex

Large-Scale Genome-Wide Association Studies and Meta-Analyses of Longitudinal Change in Adult Lung Function

Millennia Foy, Matthew Kowgier, Tamara B. Harris, Wei Gao et autres

3 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.